Literature DB >> 35690244

Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach.

Geir Bjørklund1, Maksim Pivin2, Tony Hangan3, Oksana Yurkovskaya2, Lyudmila Pivina4.   

Abstract

Autoimmune polyendocrine syndrome type 1 (APS-1) is an autosomal recessive hereditary pathology that develops with endocrine and non-endocrine manifestations in childhood. The classic triad of APS-1 includes chronic candidiasis of the skin and mucous membranes, adrenal insufficiency, and hypoparathyroidism. APS-1 is often accompanied by hypogonadism, type 1 diabetes, autoimmune thyroiditis, vitiligo, alopecia, asplenia, pneumonitis, gastritis, pernicious anemia, and intestinal dysfunction, nephritis, and hepatitis. The prevalence rate is highest in genetically isolated populations (up to 1:6500-1:9000). APS-1 occurs because of mutations in the autoimmune regulator (AIRE) gene, leading to a disrupted mechanism of normal antigen expression, the formation of abnormal clones of immune cells, and autoimmune damage to various organs. Analysis of the AIRE gene is the main diagnostic method for early detection of APS-1 and the choice of methods for its treatment. Timely genetic counseling makes it possible to identify the disease early, prescribe appropriate treatment and prevent serious complications. This paper analyzes scientific information characterizing clinical manifestations of autoimmune polyendocrine syndrome type 1 in association with its pathogenetic features, epidemiology, and current management.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AIRE gene; Autoimmune polyendocrine syndrome-1; Clinical manifestations; Epidemiology; Genetic predisposition

Mesh:

Year:  2022        PMID: 35690244     DOI: 10.1016/j.autrev.2022.103135

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   17.390


  1 in total

1.  A non-classical presentation of APECED in a family with heterozygous R203X AIRE gene mutation.

Authors:  R Giorgio; P Anne; F Roberto; L Silvia; G Nicoletta; B Corrado
Journal:  J Endocrinol Invest       Date:  2022-10-17       Impact factor: 5.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.